Fred Hutchinson Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fred Hutchinson Cancer Center sits in the top decile of US sponsors by registered trial count (#76 of 15,742 sponsors by registered trial count).
Fred Hutchinson Cancer Center: 483 sponsored US clinical trials, 57 recruiting.
Fred Hutchinson Cancer Center sponsors 483 registered US clinical trials on ClinicalTrials.gov, 57 of them currently recruiting, and 327 completed. 27 of these trials are in Phase 3-4 (later-stage) and 304 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 10 trials.
Top-decile sponsor footprint
Fred Hutchinson Cancer Center ranks in the top decile of sponsors by registered trial count (#76 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
327 of 391 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
483 total, page 6 of 10
Diet and Systemic Inflammation
NCT01424306
Scleroderma Treatment With Autologous Transplant (STAT) Study
NCT01413100
Cervical Cancer Screening Among Hispanic Women
NCT01525433
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
NCT01427881
PATH Partnering to Achieve Tobacco-free Health
NCT01533974
Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT01342887
Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
NCT01335932
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
NCT01206309
Clofarabine and Low-Dose Total-Body Irradiation in Treating Patients With Acute Myeloid Leukemia Undergoing Donor Peripheral Blood Stem Cell Transplant
NCT01252667
Meals and Grazing Study
NCT02548026
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
NCT01251575
Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy
NCT01235572
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells
NCT01097057
MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation
NCT01178892
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
NCT01231412
Vitamin D, Diet and Activity Study
NCT01240213
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
NCT00992446
Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
NCT01141725
Effects of Sulforaphane on Normal Prostate Tissue
NCT00946309
Malaria Clinical Trials Center General Screening
NCT02119312
WebQuit Online Smoking Cessation Study
NCT01166334
Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01076270
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01028716
Screening Mammography and Latinas: A Multilevel Intervention
NCT02010008
Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients
NCT01141959
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
NCT00988715
Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant
NCT01083706
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
NCT01106235
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
NCT01008462
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
NCT00968630
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD
NCT00914940
A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women
NCT01121640
Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
NCT00919503
Health SMART (Stress Management and Relaxation Training)
NCT01048528
MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women
NCT00894543
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma
NCT00945269
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00918723
Low-Dose Prednisone or Methylprednisolone in Treating Patients With Newly Diagnosed Acute Graft-versus-Host Disease
NCT00929695
TCAD vs. Monotherapy for Influenza A in Immunocompromised Patients
NCT00867139
O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas
NCT00669669
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant
NCT00796068
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
NCT00867529
Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant
NCT00839956
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
NCT00860574
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma
NCT00871481
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
NCT00860171
Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT00844441
Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS
NCT00839982
Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer
NCT00789776
Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma
NCT00793572
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 144 |
| Phase 2 | 160 |
| Phase 3 | 25 |
| Phase 4 | 2 |
Therapeutic Areas
What is open in the Fred Hutchinson Cancer Center pipeline
57 recruiting of 483 indexed (12% open); 327 completed (68%).
Phase mix: 27 late (III/IV) vs 304 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fred Hutchinson Cancer Center: open-pipeline peers nationwide
Peers matched on 483 registered trials and 12% open enrollment, not the therapeutic-area sidebar.
Fred Hutchinson Cancer Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 483 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · 490 trials · 10% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 12% open enrollment (± trial volume)
- Cochlear · 12% recruiting · 34 trials
- Erchonia Corporation · 12% recruiting · 34 trials
- Hutchmed · 12% recruiting · 17 trials
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group · 12% recruiting · 17 trials
Related
What to do with this Fred Hutchinson Cancer Center page
483 registered trials is a research-attention snapshot, not an endorsement of Fred Hutchinson Cancer Center or any single study.
- 57 of Fred Hutchinson Cancer Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition Fred Hutchinson Cancer Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Fred Hutchinson Cancer Center pipeline card: 483 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.